Peter Sand to Urinary Bladder, Overactive
This is a "connection" page, showing publications Peter Sand has written about Urinary Bladder, Overactive.
Connection Strength
9.131
-
Twelve-month Durability of a Fully-implanted, Nickel-sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence: A Single-Arm, Prospective Study. Urology. 2021 11; 157:71-78.
Score: 0.726
-
Subjective and objective responses to PTNS and predictors for success: a retrospective cohort study of percutaneous tibial nerve stimulation for overactive bladder. Int Urogynecol J. 2019 08; 30(8):1253-1259.
Score: 0.610
-
Vesico-ureteral reflux in women with idiopathic high-pressure detrusor overactivity: prevalence, bladder function, and effect on the upper urinary tract. Int Urogynecol J. 2014 Oct; 25(10):1405-10.
Score: 0.445
-
Oxybutynin: past, present, and future. Int Urogynecol J. 2013 Apr; 24(4):595-604.
Score: 0.397
-
Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studies. Drugs Aging. 2012 Feb 01; 29(2):119-31.
Score: 0.381
-
Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome. Am J Obstet Gynecol. 2012 Feb; 206(2):168.e1-6.
Score: 0.368
-
Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials. Drugs Aging. 2011 Feb 01; 28(2):151-60.
Score: 0.355
-
Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged = 75 years) with overactive bladder syndrome. BJU Int. 2011 Feb; 107(4):612-20.
Score: 0.344
-
Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement? BJU Int. 2010 Sep; 106(6):816-21.
Score: 0.332
-
Extended-release trospium chloride improves quality of life in overactive bladder. Value Health. 2010 Mar-Apr; 13(2):251-7.
Score: 0.324
-
The evolution of transdermal therapy for overactive bladder. Curr Urol Rep. 2009 Sep; 10(5):338-41.
Score: 0.322
-
Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct. 2009 Dec; 20(12):1431-8.
Score: 0.322
-
Efficacy and tolerability of fesoterodine in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 2009 Jul; 20(7):827-35.
Score: 0.312
-
Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin. Int Urogynecol J Pelvic Floor Dysfunct. 2009 Jun; 20(6):667-75.
Score: 0.311
-
Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study. Pharmacoeconomics. 2009; 27(4):329-39.
Score: 0.307
-
Predictors of persistent detrusor overactivity after transvaginal sling procedures. Am J Obstet Gynecol. 2008 Dec; 199(6):696.e1-7.
Score: 0.303
-
Subjective measures of efficacy and quality of life in overactive bladder syndrome. Curr Urol Rep. 2008 Sep; 9(5):368-72.
Score: 0.300
-
Botulinum toxin A in the overactive bladder: current status and future directions. BJU Int. 2007 Feb; 99(2):247-62.
Score: 0.269
-
Detrusor overactivity and urge urinary incontinence following trans obturator versus midurethral slings. Neurourol Urodyn. 2007; 26(1):42-5.
Score: 0.268
-
Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int. 2007 Apr; 99(4):836-44.
Score: 0.267
-
Cognitive changes in women starting anticholinergic medications for overactive bladder: a prospective study. Int Urogynecol J. 2020 Dec; 31(12):2653-2660.
Score: 0.164
-
A Prospective Study to Evaluate Efficacy Using the Nuro Percutaneous Tibial Neuromodulation System in Drug-Naïve Patients With Overactive Bladder Syndrome. Urology. 2019 Sep; 131:77-82.
Score: 0.158
-
Predictors of successful percutaneous tibial nerve stimulation (PTNS) in the treatment of overactive bladder syndrome. Int Urogynecol J. 2019 10; 30(10):1735-1745.
Score: 0.153
-
Is There a Relationship Between Patient-Reported Satisfaction and Persistence on Overactive Bladder Syndrome Pharmacotherapy? Female Pelvic Med Reconstr Surg. 2018 May/Jun; 24(3):237-240.
Score: 0.147
-
OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial. J Urol. 2017 02; 197(2S):S216-S223.
Score: 0.134
-
Does physician specialty affect persistence to pharmacotherapy among patients with overactive bladder syndrome? Int Urogynecol J. 2017 Mar; 28(3):409-415.
Score: 0.130
-
Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study. J Urol. 2016 Sep; 196(3):791-800.
Score: 0.127
-
OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013 Jun; 189(6):2186-93.
Score: 0.101
-
Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB. Int Urogynecol J. 2012 Aug; 23(8):1017-25.
Score: 0.095
-
Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms. Neurourol Urodyn. 2011 Sep; 30(7):1214-9.
Score: 0.090
-
Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms. Curr Med Res Opin. 2011 May; 27(5):921-30.
Score: 0.089
-
Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. Int J Clin Pract. 2009 Dec; 63(12):1715-23.
Score: 0.082
-
Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol. 2009 Apr; 181(4):1764-72.
Score: 0.078
-
Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology. 2008 Mar; 71(3):449-54.
Score: 0.073
-
Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol. 2007 Dec; 178(6):2488-94.
Score: 0.071
-
Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol. 2007 Sep; 178(3 Pt 1):978-83; discussion 983-4.
Score: 0.069
-
Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther. 2006 Nov; 28(11):1935-46.
Score: 0.066
-
Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference. Clin Drug Investig. 2011; 31(8):559-571.
Score: 0.022
-
Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn. 2009; 28(4):287.
Score: 0.019